Clinical trial phases, explained

When you see a clinical trial described as “Phase 1,” “Phase 2,” or “Phase 3,” these phases describe where the trial sits in the drug-development process — not how advanced your cancer needs to be. Understanding phases helps you evaluate whether a trial is appropriate for your situation.

Phase 1 — Dose finding and early safety

Purpose: Determine a safe dose and identify common side effects. Typical size: 20–100 participants. What it’s testing: Usually a new drug in humans for the first time (or a new drug combination). The main question is: what dose can we give without unacceptable toxicity?

For patients: Phase 1 trials historically enrolled only patients with advanced disease who had exhausted standard options. That’s changing — modern targeted and immune therapies sometimes make Phase 1 relevant earlier. But in general, Phase 1 implies the most unknown about efficacy.

Key questions to ask a Phase 1 trial:

• Is this the first-in-human dose escalation, or a later cohort?
• What signals of activity have been seen at higher dose levels?
• What’s the side effect profile so far?

Phase 2 — Efficacy signal

Purpose: Does the drug actually work against this cancer? Typical size: 100–300 participants. What it’s testing: The drug at the dose Phase 1 established, in a specific cancer type. Researchers are looking for a response rate, progression-free survival, or another efficacy signal.

For patients: Phase 2 trials often have clearer expected benefit than Phase 1. They’re a reasonable option when standard therapy is limited or when the trial targets a specific biomarker your cancer has.

Phase 3 — Comparison to current best care

Purpose: Is the new therapy better than the current standard of care? Typical size: 300–3,000+ participants. What it’s testing: A head-to-head comparison. Patients are randomized — by computer assignment — to receive either the new therapy or the standard. Neither the patient nor often the doctors know which arm until the trial ends (called “blinding”).

For patients: Phase 3 trials are often the most attractive to enroll in because the control arm receives the current best available treatment. You’re guaranteed, at minimum, standard care — and potentially better. Randomization means you don’t choose the arm, which some patients find unsettling.

Key question: What is the control arm? Make sure “standard of care” is well-defined and is what you’d otherwise receive.

Phase 4 — Post-approval

Purpose: Monitor long-term safety and effectiveness in broader populations. Typical size: Thousands. What it’s testing: The drug is already FDA-approved. Phase 4 tracks how it performs in real-world use — rare side effects, how it interacts with other drugs, how it works in subpopulations not well-represented in earlier phases.

For patients: Phase 4 trials offer the approved drug with additional monitoring. Low uncertainty.

Other categories you might see

• Expanded access / compassionate use — a way to receive an experimental drug outside a formal trial, usually when no other option exists. Not a trial per se, but related.
• Pilot / feasibility studies — small, early-phase studies, sometimes informally labeled.
• Basket / umbrella trials — modern trial designs that treat multiple cancer types (basket) or test multiple drugs against one cancer (umbrella) based on molecular features.

How phase should affect your decision

Your situation	Likely best-fit phase
Standard care has worked or is likely to work	Phase 3 if available, else standard off-trial
First-line treatment, standard care reasonable	Phase 3 (with standard arm as control)
Second or third line, standard options narrowing	Phase 2 or Phase 3
No standard options left	Phase 1 and Phase 2 are mainstream consideration
Biomarker-matched targeted therapy	Any phase matched to your molecular profile

Always discuss trial options with your oncologist — the right trial depends on specifics of your case beyond just the phase.

Where to search

• Use our cancer-type-specific trial browser
• Or search directly at ClinicalTrials.gov
• Ask at an NCI-designated cancer center — they run many trials and have dedicated navigators
• See our full guide to finding a clinical trial